Jones DA, Choudry F, Mathur A

Idioma: Español
Referencias bibliográficas: 44
Paginas: 43-54
Archivo PDF: 394.61 Kb.

RESUMEN

La rápida puesta en práctica de la investigación de transferencia que se ha visto en la aplicación de la medicina regenerativa a la cardiología ha dado lugar a interesantes avances en nuestra comprensión de algunos de los mecanismos fundamentales relacionados con la biología humana. La primera generación de células utilizadas en ensayos fase I-II (principalmente células mononucleares de la médula ósea), están entrando ahora en la fase III de los ensayos clínicos, con el objetivo de producir una estrategia terapéutica basada en células que puedan cambiar el pronóstico de la enfermedad cardíaca. La primera generación de terapia celular parece haber abordado las preocupaciones de seguridad, y mostró "actividad" en numerosos meta-análisis publicados. Con los conocimientos adquiridos hasta el momento, esta disciplina se está moviendo hacia la próxima generación de células -las células modificadas-, que se han desarrollado para mostrar un fenotipo que mejorará aún más el proceso de reparación/rescate del miocardio. Este anuario cubre las últimas investigaciones básicas que pueden tener aplicación en los seres humanos próximamente, así como los resultados de los últimos ensayos clínicos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Poss KD, Wilson LG, Keating MT. Heart regeneration in zebrafish. Science 2002;298:2188-90.

2. Jopling C, Sleep E, Raya M, et al. Zebrafish heart regeneration occurs by cardiomyocyte dedifferen-tiation and proliferation. Nature 2010;464:606-9.

3. Kikuchi K, Holdway JE, Werdich AA, et al. Primary contribution to zebrafish heart regeneration by ga-ta4(+) cardiomyocytes. Nature 2010;464:601-5.

4. Porrello ER, Mahmoud AI, Simpson E, et al. Tran- sient regenerative potential of the neonatal mouse heart. Science 2011;331:1078-80.

5. Ieda M, Fu JD, Delgado-Olguin P, et al. Direct repro-gramming of fibroblasts into functional cardiomyo-cytes by defined factors. Cell 2010;142:375-86.

6. Efe JA, Hilcove S, Kim J, et al. Conversion of mouse fibroblasts into cardiomyocytes using a direct re-programming strategy. Nat Cell Biol 2011;13:215-22.

7. Oh Y, Wei H, Ma D, et al. Clinical applications of patient-specific induced pluripotent stem cells in cardiovascular medicine. Heart 2012;98:443-9.

8. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibro-blast cultures by defined factors. Cell 2006:126: 663-76.

9. Okita K, Nagata N, Yamanaka S. Immunogenicity of induced pluripotent stem cells. Circ Res 2011;109: 720-1.

10. Vieira JM, Riley PR. Epicardium-derived cells: a new source of regenerative capacity. Heart 2011;97:15-19.

11. Smart N, Bollini S, Dube KN, et al. De novo car-diomyocytes from within the activated adult heart after injury. Nature 2011;474:640-4.

12. Glass C, Singla DK. MicroRNA-1 transfected embry-onic stem cells enhance cardiac myocyte differen-tiation and inhibit apoptosis by modulating the PTEN/Akt pathway in the infarcted heart. Am J Phy-siol Heart Circ Physiol 2011;301 :H2038-49.

13. Jakob P, Landmesser U. Role of microRNAs in stem/ progenitor cells and cardiovascular repair. Cardio-vasc Res 2012;93:614-22.

14. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-5.

15. Lovell MJ, Mathur A. Cardiac stem cell therapy: progress from the bench to bedside. Heart 2010; 96:1531-7.

16. Clifford DM, Fisher SA, Brunskill SJ, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2012;2:CD006536.

17. Martin-Rendon E, Brunskill SJ, Hyde CJ, et al. Auto-logous bone marrow stem cells to treat acute myo-cardial infarction: a systematic review. Eur Heart J 2008;29:1807-18.

18. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myo-cardial infarction: the BOOST randomised con- trolled clinical trial. Lancet 2004;364:141-8.

19. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarc-tion: 5-year follow-up from the randomized-con-trolled BOOST trial. Eur Heart J 2009;30:2978-84.

20. Schachinger V, Erbs S, Elsasser A, et al. Intraco-ronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355:1210-21.

21. Assmus B, Rolf A, Erbs S, et al. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocar-dial infarction. Circ Heart Fail 2010;3:89-96.

22. 2011 AHASS. Late-breaking clinical trial/clinical science: special reports abstracts. Circulation 2011; 124:2365-75.

23. Beitnes JO, Hopp E, Lunde K, et al. Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocar-dial infarction: the ASTAMI randomised, controlled study. Heart 2009;95:1983-9.

24. Yousef M, Schannwell CM, Kostering M, et al. The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol 2009;53: 2262-9.

25. Hirsch A, Nijveldt R, van der Vleuten PA, et al. Intra-coronary infusion of mononuclear cells from bone marrow or peripheral blood compared with stan-dard therapy in patients after acute myocardial infarction treated by primary percutaneous coro-nary intervention: results of the randomized con-trolled HEBE trial. Eur Heart J 2011;32:1736-47.

26. Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA 2011;306: 2110-9.

27. Traverse JH, Henry TD, Vaughan DE, et al. Rationale and design for TIME: a phase II, randomized, double-blind, placebo-controlled pilot trial evalua-ting the safety and effect of timing of adminis-tration of bone marrow mononuclear cells after acute myocardial infarction. Am Heart J 2009;158: 356-63.

28. Suarder D, Schwitter J, Moccetti T, et al. Cell-based therapy for myocardial repair in patients with acute myocardial infarction: rationale and study design of the SWiss multicenter Intracoronary Stem cells Stu-dy in Acute Myocardial Infarction (SWISS- AMI). Am Heart J 2010;160:58-64.

29. Miettinen JA, Ylitalo K, Hedberg P, et al. Deter-minants of functional recovery after myocardial infarction of patients treated with bone marrow-derived stem cells after thrombolytic therapy. Heart 2010;96:362-7.

30. Reffelmann T, Konemann S, Kloner RA. Promise of blood- and bone marrow-derived stem cell trans-plantation for functional cardiac repair: putting it in perspective with existing therapy. J Am Coll Cardiol 2009;53:305-8.

31. Roncalli J, Mouquet F, Piot C, et al. Intracoronary autologous mononucleated bone marrow cell in-fusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur Heart J 2011;32:1748-57.

32. Grajek S, Popiel M, Gil L, et al. Influence of bone marrow stem cells on left ventricle perfusion and ejection fraction in patients with acute myocardial infarction of anterior wall: randomized clinical trial: impact of bone marrow stem cell intracoronary infusion on improvement of microcirculation. Eur Heart J 2010;31:691-702.

33. Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary stem cell transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail 2010; 12:721-9.

34. Perin EC, Silva GV, Henry TD, et al. A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J 2011;161:1078-87.e3.

35. Hu S, Liu S, Zheng Z, et al. Isolated coronary artery bypass graft combined with bone marrow mono-nuclear cells delivered through a graft vessel for patients with previous myocardial infarction and chronic heart failure: a single-center, randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 2011;57:2409-15.

36. Seth S, Bhargava B, Narang R, et al. The ABCD (Au-tologous Bone Marrow Cells in Dilated Cardiomyo-pathy) trial a long-term follow-up study. J Am Coll Cardiol 2010;55:1643-4.

37. Losordo DW, Henry TD, Davidson C, et al. Intra-myocardial, autologous CD34+ cell therapy for re- fractory angina. Circ Res 2011;109:428-36.

38. Chih S, Macdonald PS, McCrohon JA, et al. Granulo-cyte colony stimulating factor in chronic angina to stimulate neovascularisation: a placebo controlled crossover trial. Heart 2012;98:282-90.

39. Houtgraaf JH, den Dekker WK, van Dalen BM, et al. First experience in humans using adipose tissue-derived regenerative cells in the treatment of pa-tients with ST-segment elevation myocardial infarc-tion. J Am Coll Cardiol 2012;59:539-40.

40. Perin EC SPL, Ruiz R, Perez-Cano R, et al. Abstract 17966: first in man transendocardial injection of autologous adiPose-derived stem cells in patients with non revascularizable ischemic myocardium (PRECISE). Circulation 2010;122: A17966.

41. Hare JM, Traverse JH, Henry TD, et al. A random-ized, double-blind, placebo-controlled, dose-escal- ation study of intravenous adult human mesen-chymal stem cells (prochymal) after acute myocar-dial infarction. J Am Coll Cardiol 2009;54:2277-86.

42. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011;378:1847-57.

43. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a pros-pective, randomised phase 1 trial. Lancet 2012;379: 895-904.

44. Bartunek J, Wijns W, Dolatabadi D, et al. C-CURE Multicenter trial: lineage specific bone marrow derived cardiopoietic mesesnchymal stem cells for treatment of ischaemic cardiomyopathy. J Am Coll Cardiol 2011;57:E200.